|
|
Vaccine Detail
|
Allogeneic Melanoma Vaccine AGI-101H |
| Vaccine Information |
- Vaccine Name: Allogeneic Melanoma Vaccine AGI-101H
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007229
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- ALDH1A1
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: The vaccine was made using melanoma cells that were virally transduced with a designer cytokine gene encoding fusion protein comprising interleukin 6 (IL-6) linked with the soluble IL-6 receptor (sIL-6R), referred to as Hyper-IL-6 or H6 (Kwiatkowska-Borowczyk et al., 2018).
- Description: A cancer vaccine derived from two gentically modified human melanoma cell lines with potential antineoplastic activity. Allogeneic melanoma vaccine AGI-101H consists of a 1:1 mixture of cells from two genetically modified human melanoma cell lines, designated as Mich1H6 and Mich2H6, that have been gamma-irradiated to render the cells non-proliferative .(Kozłowska et al., 2013). Upon administration, this vaccine may stimulate a cytotoxic immune response against melanoma tumor cells (NCIT_C78861).
AGI-101H treatment activated the TNF-α and TGF-β signaling pathways and dampened IL2-STAT5 signaling in T cells, which finally resulted in the significant up-regulation of a BCL6 transcriptional repressor, a known amplifier of the proliferative capacity of central memory T cells and mediator of a progenitor fate in antigen-specific T cells. Since its initial clinical trial in 1997, the vaccine has resulted in the long-term survival of a substantial fraction of immunized patients (up to 20 years). (Czerwinska et al., 2020)
|
| Host Response |
|
|
| References |
Czerwinska et al., 2020: Czerwinska P, Rucinski M, Wlodarczyk N, Jaworska A, Grzadzielewska I, Gryska K, Galus L, Mackiewicz J, Mackiewicz A. Therapeutic melanoma vaccine with cancer stem cell phenotype represses exhaustion and maintains antigen-specific T cell stemness by up-regulating BCL6. Oncoimmunology. 2020; 9(1); 1710063. [PubMed: 32002306].
Kozłowska et al., 2013: Kozłowska A, Mackiewicz J, Mackiewicz A. Therapeutic gene modified cell based cancer vaccines. Gene. 2013; 525(2); 200-207. [PubMed: 23566846].
Kwiatkowska-Borowczyk et al., 2018: Kwiatkowska-Borowczyk E, Czerwińska P, Mackiewicz J, Gryska K, Kazimierczak U, Tomela K, Przybyła A, Kozłowska AK, Galus Ł, Kwinta Ł, Dondajewska E, Gąbka-Buszek A, Żakowska M, Mackiewicz A. Whole cell melanoma vaccine genetically modified to stem cells like phenotype generates specific immune responses to ALDH1A1 and long-term survival in advanced melanoma patients. Oncoimmunology. 2018; 7(11); e1509821. [PubMed: 30377573].
NCIT_C78861: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C78861]
|
|
